North America Lung Transplant Therapeutics Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 OVERVIEW OF NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET 15
1.4 CURRENCY AND PRICING 16
1.5 LIMITATIONS 17
1.6 MARKETS COVERED 17
2 MARKET SEGMENTATION 20
2.1 MARKETS COVERED 20
2.2 GEOGRAPHICAL SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 21
2.4 DBMR TRIPOD DATA VALIDATION MODEL 22
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 25
2.6 MULTIVARIATE MODELLING 26
2.7 MARKET END USERS COVERAGE GRID 27
2.8 PRODUCT LIFELINE CURVE 28
2.9 DBMR MARKET POSITION GRID 29
2.10 VENDOR SHARE ANALYSIS 30
2.11 SECONDARY SOURCES 31
2.12 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 35
4.1 EPIDEMIOLOGY 36
4.2 PESTEL ANALYSIS 37
4.3 PORTERS FIVE FORCES MODEL 38
5 INSURANCE AND REIMBURSEMENT - NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET 39
5.1 U.S. 39
5.2 CANADA 40
6 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: REGULATIONS 41
6.1 REGULATION IN THE U.S. 41

7 MARKET OVERVIEW 43
7.1 DRIVERS 45
7.1.1 INCREASE IN INCIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 45
7.1.2 RISE IN AIR POLLUTION AND SURGE IN SMOKING 45
7.1.3 HIGH INCIDENCE OF CHRONIC DISEASES 46
7.1.4 RISE IN CLINICAL TRIALS 46
7.1.5 INCREASING DRUG APPROVALS 47
7.2 RESTRAINTS 47
7.2.1 LESS NUMBER OF DONORS FOR ORGAN DONATION 47
7.2.2 HIGH COST OF ORGAN TRANSPLANTATION 48
7.3 OPPORTUNITIES 48
7.3.1 RISING HEALTHCARE SPENDING 48
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 49
7.3.3 TECHNOLOGICAL ADVANCEMENTS IN LUNG TRANSPLANTATION 49
7.4 CHALLENGES 50
7.4.1 STRINGENT REGULATORY FRAMEWORK 50
7.4.2 COMPLICATIONS ASSOCIATED WITH LUNG TRANSPLANTATION 50
8 IMPACT OF COVID-19 ON LUNG TRANSPLANT THERAPEUTICS MARKET 52
8.1 IMPACT ON PRICE 52
8.2 IMPACT ON DEMAND 52
8.3 IMPACT ON SUPPLY CHAIN 53
8.4 STRATEGIC INITIATIVES 53
8.5 CONCLUSION 53
9 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT 54
9.1 OVERVIEW 55
9.2 IMMUNOSUPPRESSANT DRUGS 57
9.2.1 BY CLASS 58
9.2.1.1 CALCINEURIN INHIBITORS 59
9.2.1.1.1 TACROLIMUS 59
9.2.1.1.2 CYCLOSPORIN 59
9.2.1.2 ANTIMETABOLITE IMMUNOSUPPRESANTS 59
9.2.1.2.1 MYCOPHENOLATE MOFETIL 60
9.2.1.2.2 MYCOPHENOLATE SODIUM 60
9.2.1.2.3 AZATHIOPRINE 60
9.2.1.3 M-TOR INHIBITOR 60
9.2.1.3.1 SIROLIMUS 60
9.2.1.3.2 EVEROLIMUS 60

9.2.1.4 STEROIDS 60
9.2.1.4.1 METHYLPREDNISOLONE 61
9.2.1.4.2 PREDNISONE 61
9.2.1.5 MONOCLONAL ANTIBODY 61
9.2.1.5.1 BASILIXIMAB 61
9.2.1.5.2 MUROMONAB 61
9.2.1.6 OTHERS 62
9.2.2 BY DRUG TYPE 62
9.2.2.1 BRANDED 62
9.2.2.2 GENERIC 62
9.2.3 ROUTE OF ADMINISTRATION 62
9.2.3.1 ORAL ADMINISTRATION 62
9.2.3.2 PARENTERAL ADMINISTRATION 63
9.3 ORGAN PRESERVATION PRODUCTS 63
9.3.1 PERFADEX 64
9.3.2 HUMAN BIOSYSTEM (HBS) SOLUTION 64
9.3.3 LIFOR 64
9.3.4 CUSTODIOL HTK-(HISTIDINE-TRYPTOPHAN-KETOGLUTARATE) SOLUTION 64
9.3.5 RENOGRAF 64
9.3.6 OTHERS 64
9.4 TISSUE PRODUCT 64
9.5 OTHERS 65
10 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE 66
10.1 OVERVIEW 67
10.2 SINGLE-LUNG TRANSPLANT (SLT) 70
10.3 DOUBLE LUNG TRANSPLANT 70
10.4 BILATERAL LUNG TRANSPLANT (BLT) 70
10.5 HEART-LUNG TRANSPLANT 71
11 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS 72
11.1 OVERVIEW 73
11.2 ADULTS 75
11.3 GERIATRIC 76
11.4 PEDIATRIC 76
12 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE 78
12.1 OVERVIEW 79
12.2 CADAVERIC LUNG TRANSPLANT 81
12.3 LIVING LUNG TRANSPLANT 82
13 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION 83
13.1 OVERVIEW 84
13.2 CYSTIC FIBROSIS 87
13.3 PULMONARY FIBROSIS 87
13.4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 87
13.5 INTERSTITIAL PULMONARY FIBROSIS 88
13.6 PULMONARY HYPERTENSION 88
13.7 PRIMARY PULMONARY ARTERIAL HYPERTENSION 89
13.8 EMPHYSEMA 89
13.9 SARCOIDOSIS 90
13.10 SEPTIC LUNG DISEASE 90
13.11 OTHERS 91
14 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER 92
14.1 OVERVIEW 93
14.2 HOSPITAL 95
14.3 TRANSPLANT CENTERS 96
14.4 SPECIALTY CENTERS 96
14.5 OTHERS 97
15 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY COUNTRY 98
15.1 OVERVIEW 99
15.1.1 U.S. 104
15.1.2 CANADA 109
15.1.3 MEXICO 114
16 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY LANDSCAPE 119
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 119
17 SWOT ANALYSIS 120
18 COMPANY PROFILE 121
18.1 ASTELLAS PHARMA INC. 121
18.1.1 COMPANY SNAPSHOT 121
18.1.2 REVENUE ANALYSIS 121
18.1.3 PRODUCT PORTFOLIO 122
18.1.4 RECENT DEVELOPMENT 122

18.2 TRANSMEDICS (A SUBSIDIARY OF TRANSMEDICS GROUP, INC) 123
18.2.1 COMPANY SNAPSHOT 123
18.2.2 REVENUE ANALYSIS 123
18.2.3 COMPANY SHARE ANALYSIS 124
18.2.4 PRODUCT PORTFOLIO 124
18.2.5 RECENT DEVELOPMENT 124
18.3 DR. REDDYS LABORATORIES LTD. 125
18.3.1 COMPANY SNAPSHOT 125
18.3.2 REVENUE ANALYSIS 125
18.3.3 COMPANY SHARE ANALYSIS 126
18.3.4 PRODUCT PORTFOLIO 126
18.3.5 RECENT DEVELOPMENT 126
18.4 F.HOFFMANN-LA ROCHE LTD. 127
18.4.1 COMPANY SNAPSHOT 127
18.4.2 REVENUE ANALYSIS 127
18.4.3 COMPANY SHARE ANALYSIS 128
18.4.4 PRODUCT PORTFOLIO 128
18.4.5 RECENT DEVELOPMENT 128
18.5 HIKMA PHARMACEUTICALS PLC 129
18.5.1 COMPANY SNAPSHOT 129
18.5.2 REVENUE ANALYSIS 129
18.5.3 COMPANY SHARE ANALYSIS 130
18.5.4 PRODUCT PORTFOLIO 130
18.5.5 RECENT DEVELOPMENT 130
18.6 APOTEX INC 131
18.6.1 COMPANY SNAPSHOT 131
18.6.2 PRODUCT PORTFOLIO 131
18.6.3 RECENT DEVELOPMENT 131
18.7 XVIVO 132
18.7.1 COMPANY SNAPSHOT 132
18.7.2 REVENUE ANALYSIS 132
18.7.3 PRODUCT PORTFOLIO 133
18.7.4 RECENT DEVELOPMENT 133
18.8 ACCORD-UK LTD 134
18.8.1 COMPANY SNAPSHOT 134
18.8.2 PRODUCT PORTFOLIO 134
18.8.3 RECENT DEVELOPMENT 134

18.9 BIOLIFE SOLUTIONS 135
18.9.1 COMPANY SNAPSHOT 135
18.9.2 REVENUE ANALYSIS 135
18.9.3 PRODUCT PORTFOLIO 136
18.9.4 RECENT DEVELOPMENT 136
18.10 BRIDGE TO LIFE LTD 137
18.10.1 COMPANY SNAPSHOT 137
18.10.2 PRODUCT PORTFOLIO 137
18.10.3 RECENT DEVELOPMENT 137
18.11 DETRAXI, INC. 138
18.11.1 COMPANY SNAPSHOT 138
18.11.2 PRODUCT PORTFOLIO 138
18.11.3 RECENT DEVELOPMENT 138
18.12 INTAS PHARMACEUTICALS LTD. 139
18.12.1 COMPANY SNAPSHOT 139
18.12.2 PRODUCT PORTFOLIO 139
18.12.3 RECENT DEVELOPMENT 139
18.13 NOVARTIS AG 140
18.13.1 COMPANY SNAPSHOT 140
18.13.2 REVENUE ANALYSIS 140
18.13.3 PRODUCT PORTFOLIO 141
18.13.4 RECENT DEVELOPMENT 141
18.14 PANACEA BIOTEC LTD. 142
18.14.1 COMPANY SNAPSHOT 142
18.14.2 REVENUE ANALYSIS 142
18.14.3 PRODUCT PORTFOLIO 143
18.14.4 RECENT DEVELOPMENT 143
18.15 PARAGONIX TECHNOLOGIES, INC 144
18.15.1 COMPANY SNAPSHOT 144
18.15.2 PRODUCT PORTFOLIO 144
18.15.3 RECENT DEVELOPMENTS 144
18.15.3.1 PRODUCT LAUNCH 144
18.15.3.2 PARTNERSHIP 145
18.16 PFIZER INC. 146
18.16.1 COMPANY SNAPSHOT 146
18.16.2 REVENUE ANALYSIS 146
18.16.3 PRODUCT PORTFOLIO 147
18.16.4 RECENT DEVELOPMENT 147

18.17 VIATRIS, INC 148
18.17.1 COMPANY SNAPSHOT 148
18.17.2 REVENUE ANALYSIS 148
18.17.3 PRODUCT PORTFOLIO 149
18.17.4 RECENT DEVELOPMENT 149
18.18 21ST CENTURY MEDICINE 150
18.18.1 COMPANY SNAPSHOT 150
18.18.2 PRODUCT PORTFOLIO 150
18.18.3 RECENT DEVELOPMENT 150
19 QUESTIONNAIRE 151
20 RELATED REPORTS 155